Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat.

July 31, 2026

Vol.52 No.30

In Brief

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

LSU Health New Orleans received a five-year, $3.1 million NIH grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer have reported that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

July 17, 2026

Vol.52 No.28

In Brief

Ned Sharpless’s portrait unveiled at FNIH ceremony

Former NCI director Norman “Ned” Sharpless had his portrait unveiled at a ceremony hosted by the Foundation for the National Institutes of Health on the main NIH campus in Bethesda.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.

July 10, 2026

Vol.52 No.27

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

YOU MAY BE INTERESTED IN

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Ned Sharpless’s portrait unveiled at FNIH ceremony

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

YOU MAY BE INTERESTED IN

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Ned Sharpless’s portrait unveiled at FNIH ceremony

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Never miss an issue!

Login

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor